Abstract Study objective-To compare oral and implanted oestrogens for their effects in preventing postmenopausal osteoporosis.
Introduction
Peak bone mass is achieved in the fourth decade of life in both men and women, after which it decreases with age. The rate at which bone is lost accelerates in women after the menopause to the extent that they have lost half of their skeletal calcium by the age of 70. This leads to the excess of osteoporotic fractures in women compared with men. Albright et al were the first to show the value of oestrogen in preventing Patients and methods Table I shows the characteristics of the 114 women studied. They were postmenopausal as defined by amenorrhoea for at least one year with a serum follicle stimulating hormone concentration of more than 15 IU/1. Bone density was compared in a control group consisting of 36 untreated women (mean age 51 8 years; median time since last menstrual period 2-0 years); 37 women (mean age 57 5 years; median time since last menstrual period 8-5 years) who had been treated with oral oestrogens for a median of 8-0 years; and 41 women (mean age 56 2 years; median time since last menstrual period 9 5 years) who had been treated with subcutaneous implants of oestradiol and testosterone for a median of 8-5 years. The women treated either orally or subcutaneously, depending on their preference, had had amenorrhoea for a median of one year before starting their treatment.
All women with a uterus who were receiving oral oestrogens had their treatment supplemented with cyclic progestogen (either the combined preparation Prempak C, containing 12 days' supply of norgestrel (23 women), or Cyclo-progynova, containing 10 days' supply of levonorgestrel (six)). Women with a uterus receiving hormonal implants were given cyclic norethisterone 5 mg daily for the first seven to 13 days of each calendar month to prevent endometrial disorders.8 Hormonal implantation was carried out under local anaesthesia during a routine visit to the clinic, the pellets being inserted into the subcutaneous fat of the anterior abdominal wall. The usual dose was oestradiol 50 mg combined with testosterone 100 mg. Rarely, the oestradiol dose was increased to 75 or 100 mg. Implantation was repeated as symptoms of the climacteric returned, at about six month intervals, and at these visits bone density was measured and hormones assayed.
Bone density was estimated in the spine at L2-4 and in the neck of the right femur with a Novo 22A BMC-LAB dual photon absorptiometer with gadolinium-153 as the source of radiation.9 The ab-BMJ VOLUME 297sorptiometer was standardised with a solution radiologically equivalent to hydroxyapatite, and the results were expressed as grams of hydroxyapatite per unit projected area of bone. The precision of this technique is 1-3% and the accuracy 2-5%. ' Statistical analysis-Data on the bone density, age, and weight of the three groups of patients were normally distributed and were therefore compared by the non-paired Student's t test. All other variables were analysed with the Mann-Whitney U test as they were not normally distributed.
Results
The women in the two treatment groups were not significantly different in terms of their age, weight, years since the menopause, duration of treatment, or duration of amenorrhoea before treatment. The women in the control group were significantly younger and were fewer years past the menopause (p< 0 01). Table II summarises the measurements of bone density and plasma concentrations of sex hormones in the three groups. Bone density was significantly increased in the women receiving subcutaneous oestradiol and testosterone compared with the two other groups. In the group receiving oral oestrogens the median serum oestradiol concentration was slightly but not significantly increased compared with that in the control group and the median follicle stimulating hormone concentration was significantly reduced but remained within the postmenopausal range. Women receiving subcutaneous oestrogen and testosterone had a significantly increased median serum oestradiol concentration and a significantly decreased follicle stimulating hormone concentration compared with the other women. The current recommended dose of oral oestrogen for relieving menopausal symptoms and protecting the skeleton is 0-625 mg or 1-25 mg conjugated equine oestrogens or the equivalent dose of oestradiol valerate." The serum oestradiol concentration at this dose will, however, be only slightly raised and the follicle stimulating hormone concentration will remain in the postmenopausal range." '" Several studies have shown that higher concentrations of oestradiol are achieved by subcutaneous implantations; the effect was cumulative when implantation was repeated every six months. II This is due to the metabolic advantages of the percutaneous route and the elimination of non-compliance, which is reputed to occur in up to 70% of women prescribed oral oestrogens as replacement treatment. '6 Despite the cumulative effects of repeated implantation on plasma oestradiol concentrations no harmful effects have been identified on blood pressure, coagulation of blood, or glucose tolerance." Percutaneous treatment is an efficient route of administering oestrogen as many metabolic changes occurring in the enterohepatic system are avoided and an appropriate ratio of oestradiol to oestrone of about 2:1 results. '8 We believe that the difference in bone density between the two treatment groups was due to the higher serum oestradiol concentrations achieved with subcutaneous implants of oestrogen (725 v 170 pmol/l).
The precise mechanism whereby patients receiving oestrogen implants gain bone is unclear. The higher serum oestradiol concentrations achieved with implantation may stimulate osteoblasts directly, leading to a true gain in bone, or may be more effective in suppressing resorption of bone, thus permitting some recovery of early postmenopausal loss of bone. All women had first started treatment on average about one year after the menopause, a time when rapid postmenopausal bone loss would be expected and therefore when most could be gained by inhibiting resorption of bone and allowing the resulting spaces to be refilled. The increase in bone mass in the women receiving subcutaneous implants was greater in the spine than in the proximal femur, probably because the vertebral bodies consist predominantly of trabecular bone, which has a greater surface area and is metabolically more active than the cortical bone, which predominates in the femoral neck.'9 Nevertheless, Keil et al suggested that even fairly short exposure to oral oestrogen within four years after the menopause may confer long term protection against fracture of the hip. 20 Despite the original suggestions of Albright et al that the collagen of the bone matrix was important,' most recent work on postmenopausal osteoporosis has concentrated on calcium and the hormones regulating calcium, with conflicting results. The generalised loss of collagen in the body that occurs with decreasing oestrogen concentrations may be the primary factor causing postmenopausal osteoporosis. The association of osteoporosis with thin skin is well recognised, and we recently showed that there is a 40% decline in the collagen content and thickness of the skin after the menopause that cannot only be prevented with oestrogen but can be corrected to normal values within nine months after the start of percutaneous treatment.2 22 Decreased skin thickness with reduced collagen content has been associated with osteoporosis in anorexia nervosa (Savvas et al, unpublished results) . The loss of collagen in the skin has been estimated at 1-3% a year and is similar to the rate at which bone is lost after the menopause, which suggests that the collagen in bone may behave similarly to that in skin.2' After loss of the matrix calcium would be lost as a secondary effect independent of dietary calcium or hormones regulating calcium. The observations that osteoporotic bone has a reduced collagen content24 and that oestrogen receptors are present on osteoblasts (F S Kaplan et al, unpublished results) support this concept.
Clearly, the cornerstone of preventing osteoporosis must now be oestrogen replacement treatment. The results of our cross sectional study confirm the protec-tive effect of oral oestrogens and show an apparent increase in bone mass after treatment with subcutaneous oestradiol and testosterone. 
